Pharmacogenomic Profiling of the South Korean Population
Author Information
Author(s): Youn Mi Seon, Ahn Se Hwan, Kim Ju Han
Primary Institution: Seoul National University College of Medicine
Hypothesis
This study aims to enhance therapeutic outcomes by providing clinicians with novel insights into the pharmacogenomic diversity of the South Korean population.
Conclusion
The study reveals significant pharmacogenetic diversity in the South Korean population, emphasizing the need for population-specific pharmacogenomic data in clinical practice.
Supporting Evidence
- 93.43% of patients required dosage adjustments for at least one drug.
- 48.74% of SKR individuals were classified as intermediate metabolizers for CYP2C19.
- The high-risk *3 allele in CYP4F2 was significantly more frequent in SKR than in other East Asian populations.
Takeaway
This study looks at how people's genes affect how they respond to medicines in South Korea, helping doctors give better treatment.
Methodology
Whole genome sequencing was conducted on 396 individuals, including healthy volunteers and patients with various diseases, to identify genotype-specific drug dosing recommendations.
Limitations
The study is limited by the sample size and the need for a larger database to better represent the South Korean population.
Participant Demographics
Participants included 99 healthy volunteers, 95 patients with chronic diseases, 81 with colon cancer, 81 with breast cancer, and 40 with gastric cancer.
Statistical Information
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website